The Buy rating and price target of $23 from Roth MKM analyst Dylan Dupuis indicate a positive outlook for Terns Pharma. This news is likely to have a positive short-term impact on TERN's stock price, as it suggests that the analyst believes the stock is undervalued and has potential for growth.